Company Overview

Grifols, S.A. is a global healthcare company specializing in the development, manufacturing, and distribution of plasma-derived medicines, diagnostic solutions, and hospital products. The company operates primarily within the biopharmaceutical, diagnostics, and medical devices industries, with a strong focus on therapies derived from human plasma. Its core products are used to treat chronic, rare, and life-threatening conditions, including immune deficiencies, infectious diseases, and coagulation disorders.

Founded in Barcelona in 1940, Grifols has evolved from a local clinical analysis laboratory into one of the world’s largest plasma-derived biopharmaceutical companies. The company’s strategic advantage lies in its vertically integrated model, controlling the plasma supply chain from collection to fractionation and commercialization, as well as its extensive global plasma collection network and long-standing scientific expertise in plasma biology.

Business Operations

Grifols operates through four primary business segments: Bioscience, Diagnostic, Hospital, and Bio Supplies. The Bioscience segment is the largest revenue contributor, encompassing plasma-derived therapies such as immunoglobulins, albumin, and clotting factors. The Diagnostic segment focuses on in-vitro diagnostic systems, reagents, and blood screening technologies. The Hospital segment provides intravenous solutions, clinical nutrition, and medical devices, while Bio Supplies supports research and pharmaceutical manufacturing with plasma-based raw materials and services.

The company conducts operations across both domestic and international markets, with a particularly strong operational presence in North America and Europe. Grifols controls a large network of plasma donation centers, advanced fractionation facilities, and R&D infrastructure. Key subsidiaries include Grifols USA, LLC, Grifols Diagnostic Solutions, and Biotest AG, the latter becoming a majority-owned subsidiary following Grifols’ acquisition of a controlling stake.

Strategic Position & Investments

Grifols’ strategic direction emphasizes expansion of plasma collection capacity, increased manufacturing efficiency, and long-term investment in plasma-derived innovation. Growth initiatives have included capacity expansions in plasma centers, investments in new fractionation plants, and optimization of its global supply chain to meet rising demand for immunoglobulin therapies.

Major investments and acquisitions include the integration of Biotest AG, which strengthened Grifols’ position in plasma protein therapies and expanded its European manufacturing footprint. The company continues to invest in emerging therapeutic applications of plasma proteins, advanced diagnostic technologies, and digital solutions aimed at improving donor engagement and operational efficiency. While debt levels and capital structure have been areas of public scrutiny, available public disclosures confirm ongoing asset optimization and divestment initiatives to strengthen the balance sheet.

Geographic Footprint

Grifols is headquartered in Spain, with its principal executive offices in Barcelona. The company has a significant presence in North America, particularly the United States, which represents its largest market and hosts the majority of its plasma donation centers and a substantial portion of its revenue generation.

Beyond Europe and North America, Grifols maintains operations and commercial activities across Latin America, Asia-Pacific, and parts of Africa. Its products are sold in more than 100 countries, and the company’s international investment footprint reflects a strategy of proximity to both plasma donors and end markets, enabling regulatory alignment and logistical efficiency.

Leadership & Governance

Grifols is a founder-led company with continued involvement from the Grifols family, which remains influential through board representation and long-term strategic stewardship. The leadership structure separates executive management from board oversight, with an emphasis on scientific innovation, operational discipline, and long-term value creation.

Key executives include:

• Nacho Abia – Chief Executive Officer
• Thomas Glanzmann – Executive Chairman
• Víctor Grífols Deu – Co-Chief Executive Officer
• Antonio Martínez – Chief Financial Officer
• Deborah E. Levy – Chief Legal Officer and Corporate Secretary

The leadership philosophy centers on maintaining Grifols’ scientific leadership in plasma-derived therapies while balancing growth investments with financial sustainability and governance transparency.